Chloramidine/Bisindolylmaleimide-I-Mediated Inhibition of Exosome and Microvesicle Release and Enhanced Efficacy of Cancer Chemotherapy by Kosgodage, Uchini S et al.
Research Archive
Citation for published version:
Uchini S. Kosgodage, Rita P. Trindade, Paul R. Thompson, 
Jameel M. Inal, and Sigrun Lange, 
‘Chloramidine/Bisindolylmaleimide-I-Mediated Inhibition of 
Exosome and Microvesicle Release and Enhanced Efficacy of 
Cancer Chemotherapy’, International Journal of Molecular 
Sciences, Vol. 18 (5): 1007, May 2017.
DOI:
http://dx.doi.org/10.3390/ijms18051007
Document Version:
This is the Published version. 
Copyright and Reuse: 
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. 
This article is an open access article distributed under the 
terms and conditions of the Creative Commons Attribution 
(CC BY) license 
( http://creativecommons.org/licenses/by/4.0/ ).
Enquiries
If you believe this document infringes copyright, please contact the 
Research & Scholarly Communications Team at rsc@herts.ac.uk
 International Journal of 
Molecular Sciences
Article
Chloramidine/Bisindolylmaleimide-I-Mediated
Inhibition of Exosome and Microvesicle Release and
Enhanced Efficacy of Cancer Chemotherapy
Uchini S. Kosgodage 1, Rita P. Trindade 2, Paul R. Thompson 3, Jameel M. Inal 1,* and
Sigrun Lange 2,4,*
1 Cellular and Molecular Immunology Research Centre, School of Human Sciences,
London Metropolitan University, 166-220 Holloway Road, London N7 8DB, UK;
uck0002@my.londonmet.ac.uk
2 University College London School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK;
ana.trindade.14@ucl.ac.uk
3 Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School,
Worcester, MA 01655, USA; Paul.Thompson@umassmed.edu
4 Department of Biomedical Sciences, University of Westminster, 115, New Cavendish Street,
London W1W 6UW, UK
* Correspondence: j.inal@londonmet.ac.uk (J.M.I.);
S.Lange@westminster.ac.uk or sigrun.lange@ucl.ac.uk (S.L.);
Tel.: +44-(0)20-7133-2122 (J.M.I.); +44-(0)20-7911-5000 (ext. 64832) (S.L.)
Academic Editor: Thomas Ritter
Received: 22 February 2017; Accepted: 3 May 2017; Published: 9 May 2017
Abstract: Microvesicle (MV) release from tumour cells influences drug retention, contributing to
cancer drug resistance. Strategically regulating MV release may increase drug retention within cancer
cells and allow for lower doses of chemotherapeutic drugs. The contribution of exosomes to drug
retention still remains unknown. Potential exosome and MV (EMV) biogenesis inhibitors, tested
on human prostate cancer (PC3) cells for their capacity to inhibit EMV release, were also tested on
PC3 and MCF-7 (breast cancer) cells for improving chemotherapy. Agents inhibiting EMV release
most significantly, whilst maintaining cell viability, were chloramidine (Cl-amidine; 50 µM) and
bisindolylmaleimide-I (10 µM). Apoptosis mediated by the chemotherapy drug 5-fluorouracil (5-FU)
was significantly enhanced in PC3 cells in the presence of both these EMV inhibitors, resulting
in a 62% (Cl-amidine + 5-FU) and 59% (bisindolylmaleimide-I + 5-FU) decrease in numbers of
viable PC3 cells compared to 5-FU alone after 24 h. For MCF-7 cells, there were similar increased
reductions of viable cells compared to 5-FU treatment alone ranging from 67% (Cl-amidine + 5-FU)
to 58% (bisindolylmaleimide-I + 5-FU). Using combinatory treatment, the two EMV inhibitors further
reduced the number of viable cancer cells tested. Neither inhibitor affected cell viability. Combining
selected EMV inhibitors may pose as a novel strategy to enhance the efficacy of chemotherapeutic
drug-mediated apoptosis.
Keywords: microvesicles; exosomes; drug retention; prostate cancer; peptidylarginine deiminase;
chloramidine; bisindolylmaleimide-I; 5-fluorouracil; multidrug resistance
1. Introduction
Exosomes and microvesicles (MVs)—also referred to as EMVs—are released from all cell types
and are key mediators of intercellular communication. EMVs comprise exosomes (40–150 nm in
diameter), released through exocytosis, and MVs (150–1000 nm in diameter) that bud off directly from
the plasma membrane [1,2]. These vesicles carry lipids and proteins characteristic of their parental
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cells and affect the physiology of recipient cells by inducing intracellular signalling following receptor
binding or by delivering new receptors, enzymes, cytokines, or even genetic material, including
miRNA [3].
Multidrug resistance (MDR) describes the capacity of cancer cells to resist chemotherapy. Due
to our incomplete understanding, MDR has become a major challenge to effective treatment [4]. It is
known that cancer cells use ATP-dependent and an independent efflux of various cancer drugs [5].
Whilst many of the MDR proteins belong to the ATP-binding cassette (ABC) transporter family [6–8],
including MDR protein (MRP), Breast Cancer Resistance Protein (BCRP), and P-glycoprotein (P-gp),
some, such as lung-resistance related protein (LRP), are not ABC transporters and yet are still involved
in drug uptake [9].
EMVs can also transfer P-gp, which is involved in MDR [10], and as any change in EMV-mediated
communication is likely to affect MDR [11,12], regulation of EMVs provides a putative new strategy to
prevent MDR and improve treatment.
In cancer chemotherapy, it is essential that the drug be retained within the target cell to improve
efficacy. Microvesicle release has been shown to affect drug retention within cancer cells. This is
because chemotherapeutic drugs stimulate cells to release MVs, which we and others have shown
carry these drugs within them [12–21]. Inhibition of MV release has been shown [12–17] to increase
retention within cells and to sensitize them to chemotherapy. The aim of this study was to measure
the capacity of various candidate EMV inhibitors to inhibit EMV release from prostate cancer cells
(PC3). Following previous work in our lab, in which MV inhibitors calpeptin and chloramidine
(Cl-amidine) rendered PC3 cells more sensitive to chemotherapy, in the same vein we tried some of
the new inhibitors as well as combinations of these inhibitors (some of which also inhibited exosome
release) in experiments using 5-fluorouracil (5-FU).
2. Results
2.1. Cl-amidine, Bisindolylmaleimide-I, and Imipramine Effectively Inhibit Exosome and Microvesicle (EMV)
Release from PC3 Cells
EMVs were collected from cells after 24 h and analysed by nanoparticle tracking analysis NTA
(Figure 1A). The vesicles collected at 25,000× g were confirmed (Figure 1B) to comprise EMVs by
separate isolation of MVs (centrifugation at 10,000× g) and of exosomes (100,000× g) as determined by
electron microscopy (MVs ≥ 150 nm; exosomes ≤150 nm), by the expression of CD63 (negligible in
MVs, strong in exosomes), and by a higher PS exposition in MVs compared to exosomes. Cells were
then treated with a range of pharmacological agents and EMV counts determined by NTA analysis
(Figures 1C–E and 2A). A Guava ViaCount assay showed that the viability of cells was maintained
throughout, except with D-pantethine, which reduced viability by almost 80% (Figure 2B). Cl-amidine
(50 µM) and bisindolylmaleimide-I (10 µM) gave the maximum inhibition of EMV release resulting in
87% and 90% inhibition, respectively. Imipramine was also found to be a potent EMV inhibitor, causing
a 77% reduction in EMV count (Figure 2A). All the remaining reagents tested, except for glyburide,
also resulted in a significant inhibition. This suggests that these inhibitors are able to inhibit a range of
different pathways of EMV biogenesis and might therefore be used individually or in combination to
develop more potent EMV inhibiting strategies.
Having revealed several reagents that inhibit the total number of EMVs released from PC3 prostate
cells, the NTA data was further analysed, based on size exclusion, to verify whether the inhibition
detected was equal for typically exosome-sized vesicles (≤150 nm) and for typically MV-sized vesicles
(≥150 nm). MβCD, a commonly used endocytosis inhibitor, reduced the number of exosome-sized
vesicles compared to the untreated control by 58% and exclusively affected vesicles in this size range,
with numbers of MV-sized vesicles barely changing compared to the control (Figure 3A,B, red stars).
In contrast, Y27632, which reduced the number of MV-sized vesicles by 67%, only had a minimal
effect (3% reduction) on exosome-sized vesicles (Figure 3A,B; red stars). Bisindolylmaleimide-I,
Cl-amidine, and imipramine caused significant reductions of both ≤150-nm- and ≥150-nm-sized
Int. J. Mol. Sci. 2017, 18, 1007 3 of 12
vesicles (Figure 3A,B; black asterisks). It was noteworthy, therefore, that, according to particle
size analysis, the most effective inhibitors of EMV release, bisindolylmaleimide-I, Cl-amidine (and
imipramine) reduced numbers of both MVs and exosomes; while this was not the case with Y27632,
calpeptin, MβCD, cytochalasin D, and chlorpromazine, which showed a specific tendency to reduce
only one vesicle subtype.
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exposition. NTA analysis for released EMVs from PC3 cells are presented in the presence of Cl-
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nm were excluded to avoid including larger vesicles such as MV aggregates or apoptotic bodies. The 
experiment was repeated three times in total (error bars ± SEM, indicated in red). 
Figure 1. Nanoparticle tracking analysis (NTA) of exoso es and icrovesicles (EMVs) released from
PC3 cells in the presence of a range of EMV inhibitors. l ts resenting NTA nalysis show the
concentration of vesicl s (0–9 0 nm in diamet r) release 3 cells in the absence of any EMV
inhibitors (A); In (B) the EMVs are shown to comprise exo and microvesicles (MVs) by electron
microscopy, by Western blotting (for CD63 expression), and by the degree of phosphatidylserine (PS)
exposition. NTA analysis for released EMVs from PC3 cells are presented in the presence of Cl-amidine
(C); bisindolylmaleimide-I (D); and imipramine (E). Vesicles outside the size range of 0–900 nm were
excluded to avoid including larger vesicles such as MV aggregates or apoptotic bodies. The experiment
was repeated three times in total (error bars ± SEM, indicated in red).
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Figure 2. Pharmacological inhibition of EMV release from PC3 cells is highest with Cl-amidine,
bisindolylmaleimide-I, and imipramine. (A) Using NTA, the most significant inhibition of EMV
release from PC3 cells after 24 h was observed in the presence of Cl-amidine, bisindolylmaleimide-I,
and imipramine. After 24 h, none of the inhibitors caused any significant reduction in cell viability,
(B) except for D-pantethine. The experi ere repeated three times, and the data pr sent d are
mean ± SEM of the results. (* p ≤ .05; * p ≤ . 001).
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Figure 3. Size exclusion analysis of the NTA data, considering vesicles ≤150 nm (A) or ≥150 nm (B),
indicates percentage changes in number of exosome-sized icles (A) versus MV-sized vesicles
(B) respectively. MβCD, which only reduced exosome-sized vesicles (≤150 nm), and Y27632,
which only reduced MV-sized vesicles (≥150 nm), are both indicated by red stars. Cl-amidine,
bisindolylmaleimide-I, and imipramine, which inhibited both exosome-sized and MV-sized vesicles,
are indicated by black asterisks.
2.2. Synergistic Effect of Cl-Amidine and Bisindolyl alei ide-I on 5-FU-Mediated Apoptosis of PC3 Cells
Combinat ons of bisindolylmaleimide-I and Cl-a i re used to test for a synerg stic ffect of
EMV inhibitors in increasing the efficacy of the anti-cancer drug, 5-fluorou acil (5-FU). PC3 and MCF-7
cells were given 50 µM Cl-amidine and 10 µM bisindolylmaleimide-I separately or in combination
while adding 1 µM 5-FU; control cells were treated with 1 µM 5-FU only. After 24 h, the Guava
ViaCount cell death assay was performed on the Guava EasyCyte 8HT flow cytometer.
Int. J. Mol. Sci. 2017, 18, 1007 5 of 12
PC3 and MCF-7 cells given Cl-amidine or bisindolylmaleimide-I alongside 5-FU had a markedly
increased level of apoptosis compared to those treated with 5-FU alone (Figure 4). Combinatory
treatment with the two EMV inhibitors (50 µM Cl-amidine and 10 µM bisindolylmaleimide-I) induced
a still greater level of apoptosis in the presence of 5-FU, compared to cells treated with 5-FU alone
(Figure 4). Both bisindolylmaleimide-I and Cl-amidine on their own had negligible effects on cell
viability at 24 h (Figure 4).
Int. J. Mol. Sci. 2017, 18, 1007  5 of 11 
 
MCF-7 cells were given 50 µM Cl-amidine and 10 µM bisindolylmaleimide-I separately or in 
combination while adding 1 µM 5-FU; control cells were treated with 1 µM 5-FU only. After 24 h, the 
Guava ViaCount cell death assay was performed on the Guava EasyCyte 8HT flow cytometer. 
PC3 and MCF-7 cells given Cl-amidine or bisindolylmaleimide-I alongside 5-FU had a markedly 
increased level of apoptosis compared to those treated with 5-FU alone (Figure 4). Combinatory 
treatment with the two EMV inhibitors (50 µM Cl-amidine and 10 µM bisindolylmaleimide-I) 
induced a still greater level of apoptosis in the presence of 5-FU, compared to cells treated with 5-FU 
alone (Figure 4). Both bisindolylmaleimide-I and Cl-amidine on their own had negligible effects on 
cell viability at 24 h (Figure 4). 
 
Figure 4. Cl-amidine and bisindolylmaleimide-1-mediated inhibition of EMV release increases the 
apoptosis of PC3 and MCF-7 cells treated with 5-FU. The Guava Viacount Cell Death Assay shows 
that PC3 and MCF-7 cells that were given 5-FU together with Cl-amidine, bisindolylmaleimide-I, or 
with a combination of Cl-amidine and bisindolylmaleimide-I, had significantly reduced levels of cell 
viability within 24 h compared to PC3 and MCF-7 cells receiving no EMV inhibitors and given only 
5-FU. Bisindolylmaleimide-I and Cl-amidine had no significant effect on cell viability on their own. 
Data presented are the mean ± SEM of three independent experiments performed in triplicate (** p ≤ 
0.01; *** p ≤ 0.001; **** p ≤ 0.0001 were considered statistically significant compared to the drug-treated 
control in the absence of inhibitors). 
0
20
40
60
80
100
Cells (%)
MCF7
Dead
Apoptotic
Live
**
***
***
****
0
20
40
60
80
100
Cells (%)
PC3
Dead
Apoptotic
Live
*** *** ****
**
Figure 4. Cl-amidine and bisindolylmaleimide-1-mediated inhibition of EMV release increases the
apoptosis of PC3 and MCF-7 cells treated with 5-FU. The Guava Viacount Cell Death Assay shows that
PC3 and MCF-7 cells that were given 5-FU together with Cl-amidine, bisindolylmaleimide-I, or with a
combination of Cl-amidine and bisindolylmaleimide-I, had significantly reduced levels of cell viability
within 24 h compared to PC3 and MCF-7 cells receiving no EMV inhibitors and given only 5-FU.
Bisindolylmaleimide-I and Cl-amidine had no significant effect on cell viability on their own. Data
presented are the mean ± SEM of three ind pendent experiments performed in triplicate (** p 0.01;
*** p ≤ 0.001; **** p ≤ 0.0001 were considered statistical y ificant compared to the drug-treated
control in the absenc of inhibitors).
3. Discussion
This study reveals a range of pharmacological agents that can effectively inhibit the release of
cellular EMVs, selectively affecting a range of pathways for EMV biosynthesis. All the prospective
inhibitors of EMV release tested, bar glyburide, resulted in a clear EMV inhibition. The first inhibitor,
EGTA, is a calcium chelator. In the case of cells stimulated to take up Ca2+, for example, through
Int. J. Mol. Sci. 2017, 18, 1007 6 of 12
stimulation of P2X7 receptors with BzATP, EGTA may result in a decrease in intracellular Ca2+, thus
preventing EMV release [22]. The second inhibitor, bisindolylmaleimide-I, is a protein kinase C (PKC)
inhibitor preventing the externalisation of phosphatidylserine (PS) [23], which is a known mechanism
that drives EMV release. The third inhibitor, imipramine, is an inhibitor of acid sphingomyelinase
aSMase. Upon activation of the ATP receptor P2X7, MV shedding is associated with rapid activation
and translocation of aSMase to the outer leaflet of the plasma membrane [24]. The fourth inhibitor,
D-pantethine, blocks the translocation of phosphatidylserine [25], resulting in the non-externalisation
of PS and therefore the inhibition of microvesiculation [26]. D-pantethine has been shown to reduce
vesicle formation in mice infected with malaria compared to that of non-pantethine treated mice [27,28].
As it inhibits MV release, it so prevents systemic sclerosis in mice, as does knocking out the ABCA1
gene [29]. The most effective inhibitor in this study, Cl-amidine, affects peptidylarginine deiminase
activation, which causes post-translational protein deimination. We have previously described a novel
pathway of MV biogenesis involving increased PAD-mediated protein deimination of cytoskeletal
actin and nuclear translocation of PADs during microvesiculation [30,31]. Our current study confirms
the effectivity of pharmacological PAD inhibition using Cl-amidine for significantly reduced cellular
EMV release, targeting both MVs as well as demonstrating a novel inhibitory effect on exosome release.
The sixth inhibitor, Y27632, is an inhibitor of Rho A. Rho-associated coiled-coil containing kinases
(ROCK) are effectors of the small GTPase Rho-kinase, which amongst its myriad functions influences
the redistribution of actin-cytoskeletal changes and regulates apoptosis-induced EMV release [32].
Inhibition by Y27632 prevents the activation of Rho A, which in turn abrogates EMV biogenesis [33].
The seventh inhibitor, calpeptin, is cell-permeable and inhibits calpain [34–36], even in the prostate
cancer cell, PC3 [37], and reduces MV release from human embryonic kidney cells damaged with
the streptococcal haemolytic exotoxin, streptolysin O [38]. The eighth inhibitor, glyburide, is another
inhibitor of the ATP-binding cassette transporter and therefore a potential MV inhibitor [26], although
in this study we found it to have no effect on EMV release. The ninth inhibitor tested, cytochalasin
D, disrupts actin filaments of the cytoskeleton [39], specifically inhibiting actin polymerization, and
it is suspected that, by modulating membrane trafficking [39], this may inhibit exosome release, as
observed from HeLa cells [40]. Our data, however, indicated only a small reduction in exosome-sized
vesicles and an increase in MV-sized vesicles. As expected, of the two endocytosis inhibitors used, both
chlorpromazine, a cationic amphipathic drug, and MβCD, which depletes the cell plasma membrane
of cholesterol [41], exclusively inhibited the release of exosome-sized vesicles.
In summary, Cl-amidine, and bisindolylmaleimide-I gave the highest inhibition of EMV release
followed by imipramine and D-pantethine as detected by NanoSight analysis (Figures 1 and 2A).
However, D-pantethine significantly affected cell viability, which was found to be only 25% after 24 h
(Figure 2B). Therefore, we chose to use Cl-amidine and bisindolylmaleimide-I, either individually or
in combination, to inhibit EMV release in further experiments. Neither of these affected cell viability,
indicating that inhibition of EMV release per se did not increase apoptosis.
Recently, we described a novel mechanism for PAD-mediated MV release. Specifically, this
work showed that pan-PAD inhibitor Cl-amidine, inhibits MV release [37]. Here, we have further
shown that, compared to other EMV inhibitors, Cl-amidine is very potent, inhibiting not only MV
but also exosomal release (i.e., EMVs). Our data suggests that, rather than using sole EMV inhibitors,
a combination of EMV inhibitors may be the way forward in enhancing the anti-neoplastic effect of
pharmacological reagents. As demonstrated here in the PC3 prostate cancer and MCF-7 breast cancer
cell lines, the percentage of viable cells was significantly lower when 5-FU treatment was carried out in
the presence of Cl-amidine and the PKC inhibitor bisindolylmaleimide-I, compared to treatment with
5-FU alone, after only 24 h. While our results clearly indicate that we have also targeted inhibition
of exosome release, this is currently based on size exclusion alone and will be followed up in our
continuing studies using selective marker analysis.
Bisindolylmaleimide-I and Cl-amidine are likely to have multi-faceted effects on cells.
As discussed by Pajak et al. [42], bisindolylmaleimide-I’s role as an anti-cancer therapeutic could
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include PKC-dependent and independent effects. These may include modulation of Wnt signalling,
elimination of anti-apoptotic proteins, induction of intrinsic apoptosis, and reversal of MDR through
restoration of sensitivity to chemotherapy, by inhibiting P-gp 1 (multidrug resistance protein 1- or
ABCB1-) mediated drug efflux [42]. In the same vein, Cl-amidine will inhibit deimination of various
known and unknown target proteins in the cell, including cytoskeletal actin and nuclear proteins such
as histones via PAD nuclear translocation—which we have previously shown to be involved in MV
biogenesis [37]. However, although in theory we cannot at present rule out possible off-target effects,
neither EMV inhibitor on its own affected cell viability in the two cancer cell lines tested or at the
concentrations used in this study.
Our previous work, using the calpain inhibitor calpeptin in the presence of 5-FU and docetaxel
on prostate cancer cells, PC3, generated promising findings where combination therapy reduced
the dose of docetaxel by 100-fold needed to produce comparable reduction in tumour volume
in vivo [14]. We went on to show that methotrexate is released from cancer cells within MVs [14]. That
chemotherapeutic drugs can be released within both exosomes and MVs has been well established
by many other groups [12–21]. As our current work has shown several EMV inhibitors including
Cl-amidine, bisindolylmaleimide-I and imipramine to be more potent even than calpeptin, this bodes
well for future targeted combination therapy. Although all the inhibitors tested affected the number
of EMVs released, methyl-β-cyclodextrin, inhibited exosome release only and Y27632 inhibited MV
release alone. For future work, it would be interesting to assess the relative contribution of inhibiting
either MV or exosome release on any sensitization of cancer cells to chemotherapy. It should be
noted that as well as possibly influencing retention of chemotherapeutic drugs within cancer cells,
EMVs may also transfer proteins involved in MDR such as P-gp [10]. Clearly therefore regulation and
manipulation of EMV release is an important consideration to improving chemotherapy.
As the expanded repertoire of EMV inhibiting agents revealed in this study may also have
the potential to sensitize cancer cells to chemotherapy, they must be further tested in vitro and
in vivo, individually and in combination, taking advantage of their inhibitory effects on different EMV
biosynthesis pathways. To increase the potency of chemotherapy further and effectively inhibit MDR,
those EMV inhibitors that inhibit both exosomes and MVs will be of priority. Combination therapy
involving selective EMV inhibitors may encourage re-testing of chemotherapeutic drugs currently not
in favour due to severe side-effects and poor effectivity (such as 5-FU treatment of prostate cancer [43]).
Additionally, looking ahead to the development of future in vivo experiments it is useful that no
pre-treatment with the EMV-inhibiting drugs was needed to enhance the chemotherapeutic effect.
4. Materials and Methods
4.1. Maintaining Cell Lines
The adherent cell lines, PC3 and MCF-7 (ECACC), were maintained at 37 ◦C/5% CO2,
in growth medium containing EMV-free Fetal Bovine Serum (Sigma-Aldrich, Dorset, UK) and
RPMI (Sigma-Aldrich). Cells were split depending on confluence every 3–5 days. Cells
were washed twice with EMV-free Dulbecco’s Phosphate Buffered Saline (DPBS; Thermo Fisher
Scientific, Renfrew, UK), prepared as described before [37] and detached with 0.25% (v/v)
trypsin/EDTA (Ethylenediaminetetraacetic acid; Sigma-Aldrich), which was removed after 10–15 min
by centrifugation twice using EMV-free DPBS at 200× g/5 min (PC3 cells) or 120× g/5 min (MCF7
cells). Exponentially growing cells with viabilities of ≥95% were used in every experiment. The
number of cells and viability were determined before all experiments using the viability assay, Guava
ViaCount (Merck Millipore, Middlesex, UK).
4.2. Testing Capacity of Pharmacological Agents to Inhibit Cellular Release of EMVs
Cells were resuspended in pre-warmed serum-free RPMI and seeded in triplicate at
3.8 × 105 cells/well in 12-well microtitre plates. EGTA (ethylene glycol-bis(β-aminoethyl
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ether)-N,N,N′,N′-tetraacetic acid; Sigma-Aldrich) (1.5 mM), bisindolylmaleimide-I (10 µM; Merck
Millipore), imipramine (25 µM; Sigma-Aldrich), D-pantethine (1 mM; Sigma-Aldrich), Cl-amidine
(50 µM; provided by P.R.Thompson), Y27632 (1 µM; Sigma-Aldrich), calpeptin (25 µM; Sigma-Aldrich),
glyburide (10 µM; Sigma-Aldrich), MβCD (10 µM; Sigma-Aldrich), cytochalasin D (10 µM;
Sigma-Aldrich), and chlorpromazine (10 µM; Sigma-Aldrich) were added separately and incubated
for 24 h at 37 ◦C/5% CO2. EMVs released were isolated (4.4) and counted (4.5).
4.3. The Effect of EMV Inhibitors on 5-FU-Mediated Apoptosis of PC3 and MCF-7 Cells
Combinations of EMV inhibitors bisindolylmaleimide-I and Cl-amidine were used to test for
a synergistic enhancement of the anti-cancer drug, 5-fluorouracil (5-FU; Sigma-Aldrich). PC3 and
MCF-7 cells were maintained as before and seeded in triplicate at 3.8 × 105 cells/well in 12-well
microtitre plates with pre-warmed RPMI 1640 (Sigma-Aldrich). They were treated, either separately
or in combination, with 10 µM bisindolylmaleimide-I and 50 µM Cl-amidine and at the same time
with 1 µM 5-FU; control cells were treated with 1 µM 5-FU only. After 24 h, a cell death assay
(Guava ViaCount, Merck Millipore) was performed using the Guava EasyCyte 8HT flow cytometer
(Merck Millipore).
4.4. Isolation of EMVs
EMVs were isolated from the cell culture supernatant by centrifuging once at 200× g/5 min to
remove cells. The supernatant was then centrifuged at 4000× g/60 min at 4 ◦C to remove cell debris
and the new supernatant again at 25,000× g/1 h/4 ◦C. The isolated EMV pellet was resuspended
in sterile-filtered (0.22 µm) EMV-free DPBS and centrifuged again at 25,000× g/1 h/4 ◦C to remove
proteins possibly bound to the EMV surface (such as albumin). The EMV pellet was resuspended in
sterile-filtered EMV-free DPBS and quantified by nanoparticle tracking analysis as described below
(4.5). Isolated EMVs were used immediately.
The EMV pellet could then be centrifuged at 11,000× g for 30 min at 4 ◦C using a Beckman-Coulter
Type 60 Ti rotor (Beckman Coulter Life Sciences, High Wycombe, UK) to separate microvesicles
(MVs) and the resultant supernatant then centrifuged at 100,000× g for 1 h at 4 ◦C using the same
rotor to isolate exosomes. Microvesicles and exosomes were characterised by flow cytometry for
Annexin V-FITC (Abcam, Cambridge, UK) binding as a measure of phosphatidylserine exposition by
transmission electron microscopy as described elsewhere [44] and by Western blotting for the exosome
marker (CD63, Abcam) as previously described [31].
4.5. Nanoparticle Tracking Analysis (NTA, NanoSight LM10) of EMVs
Samples were diluted 1:50 using sterile-filtered, EMV-free DPBS, and the minimum concentration
of samples was set as 5× 107 particles/mL. The settings at capturing stage were 8 and 13 for screen and
camera gain respectively and at the process stage set at 9 and 3 for screen gain and detection threshold,
respectively, as according to the manufacturer’s instructions (Malvern Instruments, Malvern, UK).
4.6. Flow Cytometry and Guava ViaCount Assay of EMVs
The Guava EasyCyte 8HT flow cytometer (Merck Millipore) and ViaCount assay (Merck Millipore)
were used to count and determine viability of cells treated with EMV inhibitors, as previously
described [45]. Briefly, the ViaCount assay distinguishes between viable and non-viable cells based
on the differential permeability of two DNA-binding dyes in the Guava ViaCount reagent (Merck
Millipore). The nuclear dye only stained nucleated cells, while the viability dye brightly stained
necrotic or apoptotic cells.
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4.7. Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 6 (GraphPad Software,
San Diego, CA, USA). Experiments were performed three times in triplicate. A one-way ANOVA
was performed with Tukey’s post-hoc analysis. Differences were considered significant for p ≤ 0.05
(* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001).
5. Conclusions
This study emphasises the significance of EMV inhibitors in increasing the effectiveness of
chemotherapy. Careful selection and combination of EMV inhibitors, targeting different EMV
biogenesis pathways that influence exosome as well as MV release, can significantly enhance the
effectiveness of anti-cancer drugs. The results presented in prostate and breast cancer cell lines
encourage further testing in other types of cancer. Targeted prevention of possible EMV-mediated
drug removal is likely to improve the efficacy of a range of drugs and thus poses a promising strategy
to help overcome MDR.
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